<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?</h2>
    <div class="badge">2025-09-15T14:27:00+00:00</div>
    <ul>
      <li>Shares of CorMedix CRMD have soared 59.7% in the year-to-date period.</li>
<li>In the past year, CorMedix shares have surged 83.3% against the industry’s 13.8% decline.</li>
<li>In 2025, CorMedix anticipates Melinta’s portfolio to generate $125 million to $135 million in revenues.</li>
<li>In the first half of 2025, DefenCath delivered $78.8 million in net revenues, reflecting a solid start to its commercial journey.</li>
<li>CorMedix has also raised its guidance for DefenCath sales to the range of $200-$215 million in 2025 compared with the previous expectation of $180-$200 million in sales.</li>
<li>market exclusivity through 2033.</li>
<li>Management now expects 2025 pro forma revenues in the $325-$350 million range, with the deal projected to be accretive to earnings per share by 2026.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?\n• Shares of CorMedix CRMD have soared 59.7% in the year-to-date period.\n• In the past year, CorMedix shares have surged 83.3% against the industry’s 13.8% decline.\n• In 2025, CorMedix anticipates Melinta’s portfolio to generate $125 million to $135 million in revenues.\n• In the first half of 2025, DefenCath delivered $78.8 million in net revenues, reflecting a solid start to its commercial journey.\n• CorMedix has also raised its guidance for DefenCath sales to the range of $200-$215 million in 2025 compared with the previous expectation of $180-$200 million in sales.\n• market exclusivity through 2033.\n• Management now expects 2025 pro forma revenues in the $325-$350 million range, with the deal projected to be accretive to earnings per share by 2026." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/cormedix-rallies-60-ytd-indication-142700729.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>